Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen has announced a significant merger agreement between its wholly-owned subsidiary OrthoCellix (holding Neocart product assets) and Carisma Therapeutics. The merger will result in OrthoCellix becoming a wholly-owned subsidiary of Carisma, with the following key terms:
- Ownership structure: Ocugen and concurrent investors will own approximately 90% of the combined company, while pre-merger Carisma stockholders will own 10%
- Valuation: OrthoCellix valued at $135 million (subject to adjustment), Carisma at $15 million
- Concurrent Investment: Minimum $25 million investment planned, with Ocugen committing at least $5 million
- Board composition: 6 members total - 5 designated by OrthoCellix, 1 by Carisma
The deal includes termination fees ($500,000 from Carisma or $750,000 from OrthoCellix under specific conditions), lock-up agreements, and CVRs for pre-merger Carisma stockholders. The merger is subject to stockholder approval, Nasdaq listing requirements, and other customary closing conditions.